Apimeds Pharmaceuticals US, Inc. APUS

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

or "our") entered into and closed an Agreement and Plan of Merger (the "Merger Agreement"), with

Apimeds Merger Sub, Inc., a Delaware corporation ("Merger Sub"), MindWave Innovations Inc, a Delaware corporation ("MindWave"),

Lokahi Therapeutics, Inc., a Nevada corporation ("Bio Sub"), and Erik Emerson, solely in his capacity as representative

for the Bio Business (the "Bio Business Representative"). The transactions contemplated by the Merger Agreement are

Last close 2.89 2026-10-23
Market cap $4.4M 2026-06-30 share count
52-week range 1.51 - 59.70

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.55

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
R&D $1.6M—$98.5K—
SG&A $10.3M$1.3M$648.9K—
Total operating expenses $11.9M$1.3M——
Operating income -$11.9M-$1.3M-$747.4K—
Interest expense $283.0K$117.7K$38.1K—
Net income -$6.0M-$1.4M-$777.7K—
EPS, basic -0.55-0.18-0.17—
EPS, diluted -0.55-0.18-0.17—
Shares, diluted (wtd. avg.) 10.9M7.9M4.6M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $1.6M$3.5K$410.5K$6.2K
Short-term investments $2.0M———
Total current assets $14.0M$13.1K$422.1K—
Property, plant and equipment $51.6K———
Total assets $164.2M$13.1K$422.1K—
Accounts payable —$591.2K$54.4K—
Short-term debt —$20.0K——
Total current liabilities $10.7M$1.0M$123.3K—
Total liabilities $10.8M$1.4M$390.2K—
Retained earnings -$10.4M-$4.4M-$3.0M—
Total equity $153.3M-$1.4M$31.9K-$713.6K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$8.9M-$733.5K-$627.8K—
Depreciation and amortisation $5.7K———
Stock-based compensation $1.6M—$70.0K—
Capital expenditure $57.3K———
Investing cash flow -$10.1M———
Financing cash flow $20.6M$326.5K$1.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-051139.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -8M -6M -4M -2M 0 Net income, FY2023: -777.7K Net income, FY2024: -1.4M Net income, FY2025: -6M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — — —
Gross profit — — — —
Net income — -$777.7K -$1.4M -$6.0M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed Item 1.01
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Other event Item 8.01
  • Officer or director change Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%